Cybin Inc
Change company Symbol lookup
Select an option...
CLXPF Cybin Inc
RVVTF Revive Therapeutics Ltd
SHRMF Braxia Scientific Corp
LKYSF Numinus Wellness Inc
MNMD Mind Medicine (MindMed) Inc
CMPS Compass Pathways PLC
TLIS Talis Biomedical Corp
DVN Devon Energy Corp
BCX BlackRock Resources & Commodities Strategy Trust
BRKS Brooks Automation Inc
Go


Based in Canada
Company profile

Cybin Inc., formerly Clarmin Explorations Inc., is a Canada-based life sciences company. The Company is focused on developing psychedelic pharmaceutical and non-psychedelic nutraceutical-based products. Its subsidiaries include Natures Journey Inc. and Serenity Life Sciences Inc. Serenity Life Sciences Inc. is focused on research and development of psilocybin-based medications. Natures Journey Inc. operates the Journey brand, which specializes in developing medicinal mushroom products. It has a drug delivery platform developed to administer psychedelic therapies and bypass liver metabolism. The Company also focus is on the development of treatment regimens consisting of psychedelic molecules and related clinical protocols.

Price
Delayed
$1.62
Day's Change
-0.02 (-1.22%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.66
Day's Low
1.55
Volume
(Light)

Today's volume of 200,107 shares is on pace to be much lighter than CLXPF's 10-day average volume of 781,796 shares.

200,107

North America Drug Discovery Market Report 2019-2020 & 2028 Featuring Abbott Laboratories, Merck & Co, 3M Co, Sanofi, Eli Lily and Co, Johnson & Johnson, GSK, and Agilent Technologies

4:03 am ET March 12, 2021 (Globe Newswire) Print

The "North America Drug Discovery Market 2019-2028" report has been added to ResearchAndMarkets.com's offering.

The drug discovery market for North America will grow at a CAGR of 6.57% (in revenue) for the forecast period of 2019-2028. The countries from Canada and the US together shape the market for drug discovery in this region.

Cancer is the leading cause of death in Canada. 30% of the total deaths in the country are attributed to cancer. The high pervasiveness of cancer and cancer deaths has resulted in an enhanced demand for the therapeutics associated with the small molecule in the domestic market. The nation has a well-developed infrastructure as well as expertise when it comes to engineering complex molecules for the purpose of drug discovery.

The rising dependency of companies on CROs (contract research organizations) for drug discovery is expected to further boost the growth of Canada's drug discovery market. Further, the discovery of genetic mutations and the growing level of scientific comprehension of infections at the sub-atomic level, as well as the therapeutic effectiveness of the response associated with the drug, are also expected to drive the Canadian market's growth.

The Center for Drug Development and Research in Canada has been making use of the biochemical genomics and HTS technology for the Target ID and Validation procedure. These natural product fractions and screened chemicals libraries to ensure that there is a broad scope of synthetics available for the activities associated with drugs.

Further, many organizations have been using advanced technology such as liquid-handling robots & instruments for the automatic detection of biochemical and biological activity. Canada's market has been witnessing parallel trends, and further research is expected in the years to come. These aspects are anticipated to generate numerous growth prospects for the nation's drug discovery industry.

COMPETITIVE OUTLOOK

Abbott Laboratories Inc, Merck & Co Inc, 3M Company, Sanofi, Eli Lily and Company, Johnson & Johnson, GlaxoSmithKline LLC, and Agilent Technologies Inc are some of the prominent companies in the drug discovery market.

Key Topics Covered:

1. North America Drug Discovery Market - Summary

2. Industry Outlook

2.1. Market Definition

2.2. Porter's Five Forces Model

2.3. Covid-19 and Its Impact on Drug Discovery Market

2.4. PESTLE Outlook

2.5. Regulatory Framework

2.6. Value Chain Outlook

2.7. Market Attractiveness Index

2.8. Key Insight

2.9. Market Drivers

2.9.1. Growing Aged Population

2.9.2. Technological Advancements

2.9.3. Rise in Healthcare Expenditure

2.9.4. Surge in Lifestyle-Oriented Diseases

2.10. Market Restraints

2.10.1. Delay in Product Launches

2.10.2. Restricted Growth Rate Due to Generic Drugs

2.11. Market Opportunities

2.11.1. Significant Investment by Healthcare Industries in Improving Big Data Analytical Capabilities

2.11.2. Rising Demand for Specialty Medicines

2.12. Market Challenges

2.12.1. Stringent Government Regulations

3. Drug Discovery Market Outlook - by Drug Type

3.1. Small Molecule Drug

3.2. Biologic Drug

4. Drug Discovery Market Outlook - by Technology

4.1. High Throughput Screening

4.2. Biochips

4.3. Bioinformatics

4.4. Pharmacogenomics and Pharmacogenetics

4.5. Combinatorial Chemistry

4.6. Nanotechnology

4.7. Spectroscopy

4.8. Metabolomics

4.9. Other Technologies

5. Drug Discovery Market Outlook - by Service

5.1. Drug Metabolism and Pharmacokinetics (Dmpk) Services

5.2. Chemical Services

5.3. Biological Services

5.4. Other Pharmaceutical Services

6. Drug Discovery Market Outlook - by End-User

6.1. Research Institutes

6.2. Pharmaceutical Companies

6.3. Contract Research Organizations (Cros)

6.4. Other End-Users

7. Drug Discover Market - North America

7.1. Country Analysis

7.1.1. United States

7.1.2. Canada

8. Company Profiles

8.1. 3M Company

8.2. Abbott Laboratories Inc

8.3. Agilent Technologies Inc

8.4. Antares Pharma Inc

8.5. Astrazeneca plc

8.6. Bayer AG

8.7. Becton Dickinson & Company (Bd)

8.8. Boehringer Ingelheim

8.9. Eli Lily and Company

8.10. F Hoffmann-La Roche Ltd

8.11. GlaxoSmithKline LLC

8.12. Johnson & Johnson

8.13. Merck & Co Inc

8.14. Novartis

8.15. Pfizer Inc

8.16. Sanofi

For more information about this report visit https://www.researchandmarkets.com/r/7d26uu

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

https://ml.globenewswire.com/media/908fb457-7f8e-4a08-9081-5565e3dfb3d7/small/22157-jpg.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.